TMCI NASDAQ
Treace Medical Concepts, Inc.
1W: +11.8%
1M: +1.6%
3M: +12.6%
YTD: +82.0%
1Y: -33.8%
3Y: -54.1%
5Y: -82.1%
$4.55
+0.13 (+2.94%)
Weekly Expected Move ±8.2%
$4
$4
$4
$5
$5
Credit Risk of going bust: higher than 81% of companies Debt: 19.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.16 (down 97%), Treace Medical Concepts, Inc. would be worth roughly what it owes.
Total debt $72.7M against a stock market value of $295.9M.
Distance to default 2.55 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $31.2M (short-term plus half of long-term), stock volatility 88.9%; Altman Z 0.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.16 (down 97%), Treace Medical Concepts, Inc. would be worth roughly what it owes.
Total debt $72.7M against a stock market value of $295.9M.
Distance to default 2.55 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $31.2M (short-term plus half of long-term), stock volatility 88.9%; Altman Z 0.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (40)
Treace Medical Concepts, Inc. (TMCI) – What Are Researchers Saying About This Stock?
Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
Treace Medical (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts GAAP EPS of -$0.24 beats by $0.06, revenue of $45.4M beats by $1.48M
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
Artivion (AORT) Q2 Earnings Meet Estimates
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $4.97 Average Price Target from Analysts
Treace to Present at the Sidoti Small Cap Conference
Treace Medical (TMCI) Q4 2025 Earnings Transcript
Treace Medical (TMCI) Q1 2026 Earnings Transcript
Treace reaffirms 2026 revenue of $202M-$212M while targeting $300M TAM expansion in Q3 launches
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts GAAP EPS of -$0.28 beats by $0.03, revenue of $47.2M beats by $1.15M
[10-Q] TREACE MEDICAL CONCEPTS, INC. Quarterly Earnings Report - Stock Titan
Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace Medical Concepts Reports First Quarter 2026 Financial Results
Quant snapshot: Lumentum, Fastly among top-rated names as SUI Group, Service Properties lag
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
12 Health Care Stocks Moving In Friday's Intraday Session
US Stocks Mixed; Dow Falls Over 100 Points
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Average Recommendation of “Reduce” from Analysts
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives $4.77 Average PT from Analysts
Treace Medical signals 2026 revenue target of $200M–$212M while expanding comprehensive bunion solutions
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts GAAP EPS of -$0.15 in-line, revenue of $62.5M beats by $0.63M
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
301,100 Shares in Treace Medical Concepts, Inc. $TMCI Acquired by Acuitas Investments LLC
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
Treace Medical Concepts (NASDAQ:TMCI) Trading Down 0.8% – Time to Sell?
Treace Medical Secures Up to $175 Million in Debt Financing